Table 3.

Effect of acute i.v. injection of vehicle, alosetron and tegaserod on MAP, HR, CBF and CVC of fasted rats during a prolonged period of time (140 min)

Treatment and recording period	MAP (mmHg)	HR (beats·min−1)	CBF (PU)	CVC [PU·(mmHg)−1]
Vehicle (alosetron) 25–10 min pre	85.5 ± 4.14	340 ± 7.47	164 ± 49.7	1.81 ± 0.45
Vehicle (alosetron) 5–20 min post	87.9 ± 3.90	353 ± 10.2	159 ± 51.5	1.71 ± 0.45
Vehicle (alosetron) 65–80 min post	92.3 ± 3.75*	369 ± 8.07**	139 ± 40.5	1.45 ± 0.36**
Vehicle (alosetron) 125–140 min post	91.0 ± 3.77	376 ± 10.5**	136 ± 32.2	1.46 ± 0.31**
Alosetron (0.03 mg·kg−1) 25–10 min pre	86.5 ± 4.86	341 ± 32.6	155 ± 30.3	1.75 ± 0.27
Alosetron (0.03 mg·kg−1) 5–20 min post	89.0 ± 5.71	353 ± 36.6	155 ± 31.0	1.69 ± 0.26
Alosetron (0.03 mg·kg−1) 65–80 min post	93.6 ± 4.90	376 ± 39.9	146 ± 29.6	1.52 ± 0.25
Alosetron (0.03 mg·kg−1) 125–140 min post	91.5 ± 5.45	382 ± 37.2*	141 ± 31.8	1.50 ± 0.29
Vehicle (tegaserod) 25–10 min pre	75.8 ± 2.25	344 ± 11.9	258 ± 63.0	3.45 ± 0.90
Vehicle (tegaserod) 5–20 min post	83.2 ± 2.09**	363 ± 14.3	233 ± 50.7	2.89 ± 0.59
Vehicle (tegaserod) 65–80 min post	89.9 ± 2.04**	389 ± 15.5**	205 ± 44.1	2.42 ± 0.54*
Vehicle (tegaserod) 125–140 min post	89.8 ± 2.81**	391 ± 19.8**	196 ± 47.6	2.26 ± 0.57**
Tegaserod (1 mg·kg−1) 25–10 min pre	89.1 ± 4.53	354 ± 18.1	216 ± 29.6	2.49 ± 0.36
Tegaserod (1 mg·kg−1) 5–20 min post	86.5 ± 5.22	332 ± 15.9*	218 ± 39.8	2.54 ± 0.45
Tegaserod (1 mg·kg−1) 65–80 min post	87.0 ± 2.57	360 ± 15.8	203 ± 43.8	2.26 ± 0.47
Tegaserod (1 mg·kg−1) 125–140 min post	93.1 ± 2.48	382 ± 14.9**	184 ± 39.3	2.02 ± 0.41

CBF and CVC were measured by laser Doppler flowmetry. The experimental parameters were recorded and averaged during the pre-injection and post-injection periods as indicated. Means ± SEM, n= 8–12.

^*P < 0.05,

^**P < 0.01 versus pre-injection (one-way anova for repeated measures followed by the Bonferroni test).

CBF, colonic blood flow; CVC, colonic vascular conductance; HR, heart rate; MAP, mean arterial blood pressure; PU, perfusion unit.